Previous Page
11-08 :: August 2011
nanotimes
Companies Facts
N
anophase Technologies Corporation (NASDAQ: NANX) reported financial results for the second quarter and six-month period ended June 30, 2011.
Nanophase CEO and President Jess Jankowski com- mented. “Year-to-date revenue is ahead of last year and we believe that gap will grow as we move through the second half of 2011. We look to post unusually steady performance for our company, at a higher level than last year, which was significantly better than the year before that.”
Revenue for the second quarter was $2.9 million, down approximately $0.4 million from the second quarter of 2010, which happened to be the highest revenue level reported during 2010. Second quarter 2011 revenue of $2.9 million exceeded first quarter 2011 revenue of $2.8 million, as well as three of the four quarters of 2010. Gross margin for the quarter was $1.0 million, or 34% of revenue, slightly below the 36% posted during the second quarter of 2010. The net loss for the quarter was $0.5 million, or a loss of $0.02 per share, which compares to a net loss of $0.1 million, or $0.01 per share, for the second quarter of 2010.
The balance sheet is strong with approximately $3.5 million in cash and cash equivalents. The Company has no debt.
anostart AG (OTCQX: NASRY) is increasing its stake in Singapore-based Microlight Sensors
to 31%. This stems from payment of a second tran- che from the round of financing concluded back in
2010. The additional funds will go into commercial expansion, in particular buildup of marketing and sales structures in Asia, seed financing for orders and projects, and development of innovative sensor technologies. Founded in 2006, Microlight Sensors develops optical systems, instruments, and compon- ents for optical sensor technologies.
http://www.nanostart.de http://www.nanostart-asia.com
N
anoString Technologies, Inc., announced the availability of the nCounter®
39
Rat miRNA Expres-
sion Assay Kit for use on its nCounter Analysis Sy- stem. The nCounter Rat miRNA Expression Assay Kit enables researchers to perform direct digital detec- tion and counting of tissue-specific miRNAs at single- base resolution, without the need for amplification. The kit provides the capacity to perform multiplexed profiling of more than 400 rat miRNAs in a single tube, with specificity and sensitivity comparable to qPCR. Like all nCounter assays, the kit is compatible with multiple sample types, including FFPE samples.
Moreover, the Company is initiating the first in a series of studies to evaluate the clinical utility of the NanoString Breast Cancer Intrinsic Subtyping Assay. The initial investigation will utilize samples from the TransATAC study to evaluate whether the assay, which is based on the PAM50 gene signature, can quantitate the probability of cancer recurrence in individual post-menopausal women with hormone receptor-positive, early stage breast cancer (ESBC) who have been treated with hormonal therapy.